Skip to Main Content
An official website of the United States government

Approved Projects

Here you can browse the complete list of projects on CDAS whose requests for data/biospecimens were approved.

Filter results of approved projects table below

Approved Projects
Name Principal Investigator Institution Study Date Approved Project ID
A nested case-control study of circulating per- and polyfluoroalkyl substances (PFAS) and ovarian and endometrial cancers in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Rena Jones National Cancer Institute PLCO Dec 27, 2019 2019-1010
A nested case-control study of serum levels of polyfluoroalkyl chemicals (PFCs) and renal cell carcinoma among participants in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Jonathan Hofmann National Cancer Institute PLCO Sep 28, 2017 2017-0027
An evaluation of SNP frequency, aspirin resistance, and adenoma/colorectal cancer risk in the PLCO study Holli Loomans-Kropp The Ohio State University PLCO May 9, 2022 PLCO-978
An evaluation of the association between aspirin and NSAID use and changes in body mass index on gastrointestinal cancer incidence and mortality Holli Loomans-Kropp The Ohio State University PLCO Feb 15, 2022 PLCO-907
A new mathematical model for the computation of optimal cancer surveillance schedules Johannes Reiter Stanford University NLST Feb 7, 2020 NLST-636
A new mathematical model for the computation of optimal screening frequencies for lung and colorectal cancer Johannes Reiter Stanford University PLCO Feb 7, 2020 PLCO-581
A new method to estimate the predictive value in a screening program Jian-Lun Xu NCI PLCO Feb 7, 2020 PLCO-580
A New Prediction Model for Pathological Stages and Treatments for Patients with Prostate Cancer Alfadil Hamdan Sudan University PLCO Jun 27, 2018 PLCO-377
A new standardized incidence ratio metric for second primary cancer among cancer survivors by accounting for competing risks Summer Han Stanford University School of Medicine PLCO Dec 18, 2023 PLCO-1419
An examination of the relationship between specific driver mutations, target drugs, and immunotherapies in non-small cell lung cancer survival outcomes. Lauren Connell Independent PLCO Nov 17, 2020 PLCO-691
An explainable liver disease screening-based machine learning model AngĂ©lica AtehortĂșa ISGlobal Barcelona Institute for Global Health PLCO Oct 17, 2024 PLCO-1712
Angiogenic Profile and Risk of Breast Cancer in Postmenopausal Women Roni Falk NCI PLCO Sep 24, 2010 2010-0205
An integrative validation study of circulating glycans, metabolites, lipids, autoantibodies and proteins as biomarkers for lung cancer early detection Ayumu Taguchi MD Anderson Cancer Center PLCO May 1, 2013 2013-0041
An interdisciplinary approach to investigate factors influencing the changes in age-specific incidence of ovarian cancer. Imogen Rogers University of Sussex PLCO Jul 8, 2024 PLCO-1605
Annotation-Ecient Medical Image Analysis Jianming Liang Arizona State University PLCO Apr 25, 2022 PLCOI-880
Anomaly Detection in Lung CT Scans through AWS SageMaker: A Machine Learning Approach Emma Kang University of California at Berkeley NLST Mar 11, 2024 NLST-1202
A novel accuracy metric for general M-class classification when subclasses are involved Nan Nan State University of New York at Buffalo PLCO Apr 29, 2024 PLCO-1531
A Novel Approach to Facilitate Interoperability between Clinical Decision Support Systems and Electronic Health Records Ran Wei Rutgers University - New Jersey Medical Shcool NLST May 26, 2016 NLST-222
A novel approach to lung cancer detection and prediction using biomechanics-enhanced artificial intelligence Hadi Nia Boston University NLST Jan 18, 2019 NLST-471
A novel class prediction algorithm for the analysis of nodules in NLST Emmanuel Zachariah UMDNJ-Robert Wood Johnson Medical School NLST Jun 25, 2013 NLST-24